I-Mab Biopharma, of Shanghai, and South Korean-based ABL Bio Corp. said they entered a strategic partnering agreement where ABL Bio will in-license the global rights, excluding greater China, to I-Mab's bispecific antibodies (BsAb) of undisclosed target with licensing payments of approximately $100 million in total.